N
VYNE icon

Nuveen’s VYNE Therapeutics VYNE Stock Holding History

Nuveen’s Portfolio VYNE Stock Details VYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-8,164
Closed -$1.01M – 3542
2021
Q1 		$1.01M Sell
8,164
-403
-5% -$58.4K ﹤0.01% 2881
2020
Q4 		$975K Buy
8,567
+106
+1% +$13.3K ﹤0.01% 2818
2020
Q3 		$1.01M Buy
8,461
+2,298
+37% +$268K ﹤0.01% 2684
2020
Q2 		$15.6M Buy
6,163
+4,300
+231% +$582K 0.01% 1195
2020
Q1 		$360K Buy
1,863
+1,452
+353% +$455K ﹤0.01% 2883
2019
Q4 		$137K Sell
411
-332
-45% -$111K ﹤0.01% 3105
2019
Q3 		$240K Buy
743
+15
+2% +$4.84K ﹤0.01% 3089
2019
Q2 		$314K Buy
+728
New +$360K ﹤0.01% 3113

Other funds holding VYNE

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
DA
DSC Advisors Chicago, Illinois $11M AUM 5.88% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
HVC
Healthcare Value Capital Woodcliff Lake, New Jersey $50.7M AUM 24.72% 1-Year Est. Return

Nuveen's VYNE Position: Q2 2021 in Review

Nuveen sold out of VYNE Therapeutics (VYNE) in Q2 2021, closing a stake of 8,164 shares — an estimated $1.01M sold.

Nuveen first reported a position in VYNE in Q2 2019 and held it in 8 quarters. The position peaked at $15.6M in Q2 2020. 72 funds tracked by Wall St. Rank hold VYNE as of Q2 2021.

  • Nuveen reported no remaining VYNE Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Nuveen sold 8,164 VYNE Therapeutics shares in Q2 2021, an estimated $1.01M.
  • Nuveen first reported a position in VYNE Therapeutics in Q2 2019 and held it in 8 quarters.
  • Nuveen's VYNE Therapeutics position peaked at $15.6M in Q2 2020.
  • 72 funds tracked by Wall St. Rank held VYNE Therapeutics as of Q2 2021.

Based on Nuveen's 13F filing for Q2 2021, filed 16 Aug 2021.